J
Jean Pascal Lefaucheur
Researcher at Paris 12 Val de Marne University
Publications - 27
Citations - 5513
Jean Pascal Lefaucheur is an academic researcher from Paris 12 Val de Marne University. The author has contributed to research in topics: Transcranial magnetic stimulation & Transcranial direct-current stimulation. The author has an hindex of 18, co-authored 27 publications receiving 3899 citations. Previous affiliations of Jean Pascal Lefaucheur include French Institute of Health and Medical Research & University of Paris.
Papers
More filters
Journal ArticleDOI
Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS)
Jean Pascal Lefaucheur,Nathalie André-Obadia,Andrea Antal,Samar S. Ayache,Chris Baeken,David H. Benninger,Roberto Cantello,Massimo Cincotta,Mamede de Carvalho,Dirk De Ridder,Hervé Devanne,Vincenzo Di Lazzaro,Saša R. Filipović,Friedhelm C. Hummel,Satu K. Jääskeläinen,Vasilios K. Kimiskidis,Giacomo Koch,Berthold Langguth,Thomas Nyffeler,A. Oliviero,Frank Padberg,Emmanuel Poulet,Simone Rossi,Paolo Maria Rossini,John C. Rothwell,Carlos Schönfeldt-Lecuona,Hartwig R. Siebner,Christina W. Slotema,Charlotte J. Stagg,Josep Valls-Solé,Ulf Ziemann,Walter Paulus,Luis Garcia-Larrea +32 more
TL;DR: There is a sufficient body of evidence to accept with level A (definite efficacy) the analgesic effect of high-frequency rTMS of the primary motor cortex (M1) contralateral to the pain and the antidepressant effect of HF-rT MS of the left dorsolateral prefrontal cortex (DLPFC).
Journal ArticleDOI
Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS)
Jean Pascal Lefaucheur,Andrea Antal,Samar S. Ayache,David H. Benninger,Jerome Brunelin,Filippo Cogiamanian,Maria Cotelli,Dirk De Ridder,Roberta Ferrucci,Berthold Langguth,Paola Marangolo,Veit Mylius,Michael A. Nitsche,Frank Padberg,Ulrich Palm,Emmanuel Poulet,Alberto Priori,Simone Rossi,Martin Schecklmann,Sven Vanneste,Ulf Ziemann,Luis Garcia-Larrea,Walter Paulus +22 more
TL;DR: It remains to be clarified whether the probable or possible therapeutic effects of tDCS are clinically meaningful and how to optimally perform tDCS in a therapeutic setting.
Journal ArticleDOI
Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018)
Jean Pascal Lefaucheur,André Aleman,Chris Baeken,David H. Benninger,Jerome Brunelin,Vincenzo Di Lazzaro,Saša R. Filipović,Christian Grefkes,Alkomiet Hasan,Friedhelm C. Hummel,Satu K. Jääskeläinen,Berthold Langguth,Letizia Leocani,Alain Londero,Raffaele Nardone,Jean-Paul Nguyen,Thomas Nyffeler,Albino J. Oliveira-Maia,A. Oliviero,Frank Padberg,Ulrich Palm,Walter Paulus,Emmanuel Poulet,Angelo Quartarone,Fady Rachid,Irena Rektorová,Simone Rossi,Hanna Sahlsten,Martin Schecklmann,David Szekely,Ulf Ziemann +30 more
TL;DR: These updated recommendations take into account all rTMS publications, including data prior to 2014, as well as currently reviewed literature until the end of 2018, and are based on the differences reached in therapeutic efficacy of real vs. sham rT MS protocols.
Journal ArticleDOI
Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines
Simone Rossi,Andrea Antal,Sven Bestmann,Marom Bikson,Carmen C. Brewer,Jürgen Brockmöller,Linda L. Carpenter,Massimo Cincotta,Robert Chen,Jeff D Daskalakis,Vincenzo Di Lazzaro,Michael D. Fox,Mark S. George,Donald L. Gilbert,Vasilios K. Kimiskidis,Giacomo Koch,Risto J. Ilmoniemi,Jean Pascal Lefaucheur,Letizia Leocani,Sarah H. Lisanby,Carlo Miniussi,Frank Padberg,Alvaro Pascual-Leone,Walter Paulus,Angel V. Peterchev,Angelo Quartarone,Alexander Rotenberg,John C. Rothwell,Paolo Maria Rossini,Emiliano Santarnecchi,Mouhsin M. Shafi,Hartwig R. Siebner,Yoshikatzu Ugawa,Eric M. Wassermann,Abraham Zangen,Ulf Ziemann,Mark Hallett +36 more
TL;DR: New operational guidelines are provided for safety in planning future trials based on traditional and patterned TMS protocols, as well as a summary of the minimal training requirements for operators, and a note on ethics of neuroenhancement.
Journal ArticleDOI
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial
Stéphane Palfi,Jean Marc Gurruchaga,G. Scott Ralph,Helene Lepetit,Sonia Lavisse,Philip C. Buttery,Colin Watts,James Miskin,Michelle Kelleher,Sarah Deeley,Hirokazu Iwamuro,Jean Pascal Lefaucheur,Claire Thiriez,Gilles Fénelon,Gilles Fénelon,Cherry Lucas,Pierre Brugières,Inanna Gabriel,Kou Abhay,Xavier Drouot,Naoki Tani,Aurélie Kas,Bijan Ghaleh,Philippe Le Corvoisier,Patrice Dolphin,David P. Breen,Sarah L Mason,Natalie Valle Guzman,Nicholas D. Mazarakis,Pippa A Radcliffe,Richard Harrop,Susan M. Kingsman,Olivier Rascol,Stuart Naylor,Roger A. Barker,Philippe Hantraye,Philippe Remy,Philippe Remy,Pierre Cesaro,Pierre Cesaro,Kyriacos A. Mitrophanous +40 more
TL;DR: ProSavin was safe and well tolerated in patients with advanced Parkinson's disease and a significant improvement in mean UPDRS part III motor scores off medication was recorded in all patients at 6 months and 12 months.